Nervgen Pharma Corp stock is traded at $1.32, with a volume of 83,173. It is up 0.00% in the last 24 hours and down -24.57% over the past month. NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
Previous Close:
$1.32
Open:
$1.30
24h Volume:
83,173
Relative Volume:
0.19
Market Cap:
$141.93M
Revenue:
-
Net Income/Loss:
-$31.64M
P/E Ratio:
-
EPS:
-$0.4226
Net Cash Flow:
-$13.98M
1W Performance:
-3.65%
1M Performance:
-24.57%
6M Performance:
-66.07%
1Y Performance:
0.00%
1-Day Range:
$1.29$1.33
1-Week Range:
$1.28$1.51
52-Week Range:
$1.28$6.30
Nervgen Pharma Corp Stock (NGEN) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS